Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cerecor Inc
ClinicalTrials.gov Identifier:
NCT01579526
First received: April 6, 2012
Last updated: May 16, 2012
Last verified: May 2012

April 6, 2012
May 16, 2012
April 2012
April 2012   (final data collection date for primary outcome measure)
  • Plasma pharmacokinetic profiles of the active pharmaceutical ingredient [ Time Frame: various timepoints over 72 hours ] [ Designated as safety issue: No ]
    Plasma PK profiles: various PK indices including, but not limited to, peak plasma concentration (Cmax), Area under the plasma concentration versus time curve (AUC), and elimination half-life (T1/2), and time to peak plasma concentration (Tmax).
  • Safety and Tolerability [ Time Frame: Various Timepoints over 72 Hours ] [ Designated as safety issue: Yes ]
    Safety and Tolerability will take into account the recorded AEs, vital signs, and clinical and laboratory assessments.
Same as current
Complete list of historical versions of study NCT01579526 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers
A Randomized, Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers

The purpose of this study is to determine the safety and pharmacokinetics of FP01 in healthy volunteers.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Healthy
Drug: FP01
comparison of different dosages
  • Experimental: FP01 Dose 1
    Drug
    Intervention: Drug: FP01
  • Experimental: FP01 Dose 2
    Drug
    Intervention: Drug: FP01
  • Experimental: FP01 Dose 3
    Drug
    Intervention: Drug: FP01
  • Active Comparator: Comparator
    Drug
    Intervention: Drug: FP01
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
May 2012
April 2012   (final data collection date for primary outcome measure)

INCLUSION CRITERIA

  1. Subjects are male and female volunteers 18 to 55 years of age inclusive.
  2. BMI between 18 and 30, inclusive.
  3. Subjects must have an estimated creatinine clearance rate of ≥ 80 mL/min as determined by the Cockcroft-Gault equation (see section 7.1).
  4. Female subjects of childbearing potential must be using adequate birth control as determined by the Investigator.
  5. Female subjects of childbearing potential must have negative pregnancy test results at screening and Day -1.
  6. Subjects must be able to provide informed consent after risks and benefits have been explained.
  7. Subjects must be non-smoking and non-tobacco user (defined as a subject who has not smoked or used tobacco products for ≥ 12 months from study screening), and must agree to abstain from alcohol and caffeine for 72 hours prior to study dosing and during their participation in the study.
  8. Subjects must have a 12 lead ECG without any clinically significant abnormalities of rate, rhythm, intervals or conduction, as determined by the Investigator.
  9. Subjects are in generally good health, based on pre-study medical history, physical examination and routine laboratory tests, as determined by the Investigator.
  10. Subjects who have no clinically significant disease and/or clinically significant abnormal laboratory values as determined by the Investigator based on medical history, physical examination, or laboratory evaluations conducted at the screening visit or on admission to the clinic.
  11. Be willing and able to comply with the study protocol requirements for the duration of the study, including pharmacokinetic sampling

EXCLUSION CRITERIA

  1. Females who are pregnant or lactating.
  2. Subjects who have a history of drug or alcohol abuse within 12 months of study screening, as determined by the Investigator.
  3. Subjects who have participated in any investigational trial within 30 days or six half-lives of the test drug's biologic activity, whichever is longer, before the start of the study (time of first dose).
  4. Subjects who have clinically significant medical or psychiatric illnesses currently or within 30 days of start of study (time of first dose), as determined by the Investigator.
  5. Subjects with any oral lesions observed at screening visit or at the Day -1 visit.
  6. Subjects who have a history of significant allergies (including history of asthma, food, or drug allergies), as determined by the Investigator.
  7. Subjects who have had significant blood loss, or have donated or received one or more pints of blood within 30 days prior to dosing.
  8. Subjects who have had symptoms of any significant acute illness including upper respiratory infections within 30 days prior to the start of study (time of first dose), as determined by the Investigator.
  9. Subjects who have any condition that interferes with their ability to understand or comply with the requirements of the study.
  10. Subjects who have a positive drug screen or alcohol screen at study screening or Day -1.
  11. Subjects who have any disease or condition (medical or surgical) that might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or central nervous system function; or any other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the study drug, or that would place the subject at increased risk, as determined by the Investigator.
  12. Subjects who have a positive result at screening for HIV, Hepatitis B, or Hepatitis C.
  13. Subjects who have received any concomitant prescription, over-the-counter, or herbal medications 7 days prior to study dosing, with the exception of hormonal contraceptives and up to 3 doses of acetaminophen at a dose of 1 gram or less from the time of study screening to the time of study dosing.
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01579526
Clin01-001
No
Cerecor Inc
Cerecor Inc
Not Provided
Not Provided
Cerecor Inc
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP